Therefore, the development of selective DAGLα inhibitors is of interest in reducing endocannabinoid tone in obesity, a statement supported by pharmacological manipulation of DAGLα in DIO models [87]. The gene discussed is DAGLA; the disease is obesity due to melanocortin 4 receptor deficiency.